HuVePharma
ActiveSummary
HuVePharma has been active since 2005 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €49.8m and a net result of €5.9m. Equity is growing by about 14% per year across the filed financial years. Its solvency ranks better than 51% of 6,136 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest, Uitbreidingstraat 80 2600 Antwerpen (Berchem)” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- “Iedere bestuurder die wordt aangesteld tot gedelegeerde bestuurder met alleen vertegenwoordigingsbevoegdheid, zal krachtens deze statuten…”
- Board ruleHow the board is made up, meets and takes decisions.
- “Raad van bestuur, 3” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Third Thursday of May at 15:00